Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | Spleen volume responses in fedratinib treated myelofibrosis patients

Ruben Mesa • 1 Sep 2020
SOHO 2020
Myelofibrosis Myeloproliferative Neoplasms Fedratinib
JAKARTA JAKARTA2

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, outlines the spleen volume responses as assessed in the JAKARTA study (NCT01437787), where patients with myelofibrosis were treated with fedratinib, a JAK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
The MPN Journal: a web-based platform developed by patients for patients
1:05
The MPN Journal: a web-based platform developed by patients for patients
Ruben Mesa • 6 Dec 2025
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
1:12
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
Ruben Mesa • 6 Dec 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Ruben Mesa • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Ruben Mesa • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals